April 25, 2019 07:02 AM EDT
Financing

Tout­ing su­pe­ri­or nasal de­liv­ery, Sat­suma bags $62M for new for­mu­la­tion of old mi­graine drug

Amber Tong

A sin­gle-mind­ed biotech out of South San Fran­cis­co has raised $62 mil­lion to run the last mile hop­ing to breath new life in­to a gener­ic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

A service from the Financial Times